Pigment Dispersion Syndrome

Complex MONDO:0010896 Pathograph 16 Show in embeddings browser

Pigment dispersion syndrome is an acquired anterior-segment disorder in which pigment is rubbed off the back of the iris and washed forward into the eye's drainage system. The mechanism is unusually mechanical for an eye disease: the mid-peripheral iris bows backwards into a concave configuration, which brings its pigmented posterior surface into contact with the zonular fibres that suspend the lens. Every accommodation and every blink chafes iris against zonule, liberating granules from the iris pigment epithelium. The released pigment circulates in the aqueous humour and settles wherever that fluid goes, producing the classical triad: a vertical band of pigment on the corneal endothelium, radial spoke-like transillumination defects where the iris has been scoured through, and a densely pigmented trabecular meshwork on gonioscopy. The distinction that organises this entry is that pigment dispersion is a risk state, not a glaucoma. Trabecular cells phagocytose small amounts of pigment without consequence, and many people carry a heavily pigmented meshwork and normal pressure for life. The disease becomes pigmentary glaucoma only when sustained pigment loading overwhelms that clearance capacity, outflow resistance rises, intraocular pressure climbs, and the optic nerve is damaged. The literature is explicit that the same deposited pigment behaves benignly in one eye and malignantly in another, and what determines which remains unexplained. The disease is polygenic rather than Mendelian, with a strong and probably causal relationship to myopia, and it presents young, in the third to fifth decade, in a population that is disproportionately male when glaucoma develops.

Ask OpenScientist

Ask a research question about Pigment Dispersion Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
7
Phenotypes
2
Gaps
16
Pathograph
4
Genes
3
Medical Actions
3
Differentials
1
Models
1
Deep Research
?

Discussions and Knowledge Gaps

2
Why does trabecular pigment loading raise intraocular pressure in some eyes and not others, when the deposited pigment looks the same?
KNOWLEDGE GAP OPEN pds_benign_versus_malignant_course
Attached to
pathophysiology#Trabecular Meshwork Pigment Loading and Outflow Dysfunction
This is the central unresolved question of the disease and it is unusually sharply posed, because the literature states the divergence explicitly: the same pigment carried to the same structure behaves benignly in some eyes and malignantly in others. A person may carry a densely pigmented meshwork for decades with normal pressure while another with comparable gonioscopic findings develops glaucoma. Candidate explanations include differences in trabecular phagocytic reserve, in the rate rather than the total burden of pigment delivery, in baseline outflow facility, and in genetic susceptibility at the identified association loci, but none has been shown to determine the outcome. Until it is understood, pigment burden on gonioscopy cannot be used to predict who needs treatment, which is precisely the clinical question the finding appears to answer and does not.
Proposed experiments
Longitudinal outflow facility against pigment burden in dispersion syndrome
pds_longitudinal_outflow_facility
Follow a cohort with gonioscopically graded pigment burden using serial tonography or equivalent measures of outflow facility, rather than pressure alone, and test whether baseline or declining facility separates those who convert to ocular hypertension from those who do not at equivalent pigment load. Pressure is a late and buffered readout; facility is the quantity the mechanism actually predicts.
Does flattening the iris with peripheral laser iridotomy, which demonstrably alters iris configuration, change the clinical course of pigment dispersion?
KNOWLEDGE GAP OPEN pds_iridotomy_mechanism_versus_outcome
Attached to
pathophysiology#Posterior Iris Concavity and Iridozonular Contact treatments#Peripheral Laser Iridotomy
The procedure targets the initiating mechanism directly and its anatomical effect is not in doubt, which makes it unusually persuasive. A systematic review nonetheless concludes that its effectiveness in reducing the development or progression of pigmentary glaucoma is unknown. The gap matters because mechanistic plausibility is doing the work that evidence normally would: the intervention is offered on the strength of the mechanism curated in this entry, and if pigment liberation is not in fact rate-limiting for conversion, flattening the iris could alter the anatomy without altering the outcome.
Proposed experiments
Randomised trial of iridotomy with conversion to ocular hypertension as endpoint
pds_iridotomy_conversion_trial
Randomise people with dispersion syndrome and normal pressure to iridotomy or observation, with conversion to ocular hypertension and to glaucomatous optic neuropathy as endpoints rather than iris configuration or pigment score. The anatomical effect is already established; what is missing is whether it propagates to the outcome.
⚙

Pathophysiology

6
Posterior Iris Concavity and Iridozonular Contact
The initiating mechanical fault. The mid-peripheral iris bows posteriorly into a concave configuration, which presses its pigmented back surface against the zonular fibres suspending the lens. This is anatomy rather than biochemistry: a deep anterior chamber, a wide-open angle, and the axial geometry that accompanies myopia all increase the contact, and the movements of ordinary life supply the repetition.
Downstream
Liberation of Iris Pigment Epithelial Granules Repeated mechanical contact abrades the pigmented posterior surface.
Show evidence (1 reference)
PMID:10150864 SUPPORT Human Clinical
"The concavity of the midperipheral iris allows iridozonular contact."
States the geometric fault and the contact it permits, which is the whole of this node.
Liberation of Iris Pigment Epithelial Granules
Pigment granules are released from the iris pigment epithelium, the densely pigmented layer on the posterior iris surface. The loss is structural and visible: where the epithelium has been scoured away, light passes through the iris in radial spoke-like defects, so the damage can be read directly at the slit lamp.
iris pigment epithelial cell CL:0002565 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves iris pigment epithelial cell (CL:0002565). CL:0002565 is a cell type from the Cell Ontology.
Downstream
Pigment Dispersion Through the Aqueous Humour Liberated granules enter the aqueous and are carried by its circulation.
Iris transillumination defect Loss of the pigmented layer produces the transillumination defects.
Show evidence (1 reference)
PMID:26871761 SUPPORT Human Clinical
"Pigment dispersion syndrome is characterized by a structural disturbance in the iris pigment epithelium"
Locates the structural disturbance in the iris pigment epithelium, which is the cell layer this node describes.
Pigment Dispersion Through the Aqueous Humour
Released granules circulate in the aqueous humour and deposit wherever that fluid carries them: on the corneal endothelium as a vertically oriented Krukenberg spindle, on the lens and zonules, and in the trabecular meshwork. The distribution is a map of aqueous flow rather than of disease severity, which is why the corneal and iris signs are diagnostic without being harmful.
Downstream
Trabecular Meshwork Pigment Loading and Outflow Dysfunction The consequential destination, because the meshwork is the drain.
Pigment deposition in the trabecular meshwork The visible deposit itself, seen on gonioscopy as a dense pigmented band. Kept separate from the outflow node because the sign and the functional consequence are not the same claim: a heavily pigmented angle can be present with normal pressures.
Corneal pigment deposition (Krukenberg spindle) Pigment carried by aqueous convection settles on the corneal endothelium in a vertical spindle, which is where the flow pattern of the anterior chamber writes itself onto the cornea.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
Enumerates the three deposition sites that define the clinical presentation, which is what this node distributes pigment to.
Trabecular Meshwork Pigment Loading and Outflow Dysfunction
The node where a cosmetic finding becomes a disease, and the point at which the two possible courses separate. Trabecular cells phagocytose small amounts of pigment and dispose of it without consequence, which is why a densely pigmented meshwork is compatible with a lifetime of normal pressure. Sustained loading is different: phagocytic and migratory capacity falls, trabecular cells are lost, and aqueous outflow resistance rises. The literature states the divergence directly, describing the same deposited pigment as behaving benignly in some eyes and malignantly in others.
trabecular meshwork cell CL:0002367 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves trabecular meshwork cell (CL:0002367). CL:0002367 is a cell type from the Cell Ontology.
phagocytosis of pigment granules by trabecular cells GO:0006909 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased phagocytosis of pigment granules by trabecular cells, annotated with phagocytosis (GO:0006909). GO:0006909 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
DBA/2J mouse pigmentary glaucoma Mouse partially recapitulates Reproduces the pathway from liberated iris pigment through the ocular drainage structures to raised pressure and glaucoma, which is the sequence this entry models downstream of pigment release.
Downstream
Elevated Intraocular Pressure Rising outflow resistance raises intraocular pressure. This edge fires only in the malignant course; in the benign course the node has no downstream consequence at all.
Show evidence (2 references)
PMID:10150864 SUPPORT Human Clinical
"Small amounts of pigment are quickly phagocytized."
Establishes the clearance capacity that must be exceeded before pigment loading matters, which is why this node is a threshold rather than a step.
PMID:10150864 SUPPORT Human Clinical
"Released pigment is carried to the trabecular meshwork where it resides: (1) benignly, not affecting the intraocular pressure, as in pigment dispersion syndrome; or (2) malignantly, elevating the intraocular pressure, as in pigmentary glaucoma."
The decisive sentence of the entry: the same pigment in the same place has two possible consequences, and which one occurs is what separates the syndrome from the glaucoma.
Elevated Intraocular Pressure
Sustained rise in intraocular pressure as outflow resistance exceeds what aqueous production and alternative drainage can compensate for. This node exists as a mechanism node rather than only as a clinical sign because it is the step that carries the chain forward: pigment in the meshwork does nothing to the optic nerve except through pressure, and it is the only point in the chain that current treatment can act on.
Downstream
Glaucomatous Optic Neuropathy Sustained pressure elevation damages the optic nerve head, converting the dispersion syndrome into pigmentary glaucoma.
Ocular hypertension The measurable clinical sign of this node.
Show evidence (2 references)
PMID:36518550 SUPPORT Human Clinical
"PDS is a risk factor and can give lead to a rise in intraocular pressure (IOP) and secondary glaucoma."
Establishes the rise in intraocular pressure as the consequence of the dispersion and the route to secondary glaucoma. Quoted verbatim including the source's grammatical slip.
PMID:10150864 SUPPORT Human Clinical
"Released pigment is carried to the trabecular meshwork where it resides: (1) benignly, not affecting the intraocular pressure, as in pigment dispersion syndrome; or (2) malignantly, elevating the intraocular pressure, as in pigmentary glaucoma."
The same sentence that establishes the threshold upstream also names pressure elevation as the discriminating consequence, which is why this node is the branch point between the two courses.
Glaucomatous Optic Neuropathy
Retinal ganglion cell loss with optic disc and nerve fibre layer damage, and the point at which the diagnosis changes name. Pigmentary glaucoma requires this node; dispersion syndrome with a heavily pigmented meshwork and a normal disc does not qualify, however dramatic the anterior-segment findings.
Downstream
Glaucoma Optic neuropathy with characteristic field loss is what converts pigment dispersion syndrome into pigmentary glaucoma. This edge is the diagnostic threshold rather than a separate biological step.
Visual field defect Ganglion cell loss produces the characteristic field defects.
Show evidence (2 references)
PMID:36518550 SUPPORT Human Clinical
"Pigmentary glaucoma (PG) can develop from PDS in the presence of elevated IOP coupled with glaucomatous optic neuropathy, retinal nerve fiber thinning, and/or visual field defects."
States the diagnostic requirement precisely: elevated pressure together with optic neuropathy, not pigment alone.
PMID:26871761 SUPPORT Human Clinical
"Pigmentary glaucoma is a specific form of open-angle glaucoma found in patients with pigment dispersion syndrome."
Places pigmentary glaucoma as a subset arising within the dispersion population rather than as a separate disease.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pigment Dispersion Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Eye 3
Glaucoma HP:0000501 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pigmentary glaucoma, annotated with Glaucoma (HP:0000501). HP:0000501 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26871761 SUPPORT Human Clinical
"Pigmentary glaucoma is a specific form of open-angle glaucoma found in patients with pigment dispersion syndrome."
Defines the phenotype as an open-angle glaucoma arising in this specific population.
Myopia HP:0000545 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myopia (HP:0000545). HP:0000545 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36518550 SUPPORT Human Clinical
"It is more common in myopic patients with a predominance in young males in the third to fifth decade of life that affects about 1-2% of the population."
Gives the myopic predominance, the sex skew, and the age of presentation in one sentence. No frequency band is assigned: the sentence establishes that the disease is more common in myopic patients without quantifying the proportion of patients who are myopic, and a band would assert a number the source does not report.
Visual field defect HP:0001123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual field defect (HP:0001123). HP:0001123 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36518550 SUPPORT Human Clinical
"Pigmentary glaucoma (PG) can develop from PDS in the presence of elevated IOP coupled with glaucomatous optic neuropathy, retinal nerve fiber thinning, and/or visual field defects."
Names visual field defects among the findings that establish glaucomatous damage.
Other 4
Iris transillumination defect HP:0012805 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Iris transillumination defect (HP:0012805). HP:0012805 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
Names both the corneal deposition and the iris transillumination defects that this phenotype covers.
Pigment deposition in the trabecular meshwork HP:0012631 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pigment deposition in the trabecular meshwork (HP:0012631). HP:0012631 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
Names increased trabecular meshwork pigmentation among the three defining clinical findings.
Corneal pigment deposition (Krukenberg spindle)
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
Names pigmented cells on the corneal endothelium as the first of the three defining findings. Left unbound because HPO has no Krukenberg spindle or corneal endothelial pigment term; the finding is described rather than forced onto a poor fit.
Ocular hypertension HP:0007906 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ocular hypertension (HP:0007906). HP:0007906 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36518550 SUPPORT Human Clinical
"PDS is a risk factor and can give lead to a rise in intraocular pressure (IOP) and secondary glaucoma."
Establishes raised intraocular pressure as a consequence of the dispersion rather than an independent finding. Quoted verbatim including the source's grammatical slip.
🧬

Genetic Associations

4
Polygenic susceptibility to pigment dispersion
relationship_type: SUSCEPTIBILITY
Show evidence (3 references)
PMID:30796891 SUPPORT Human Clinical
"Pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) are presumed to be inherited in an autosomal dominant manner."
PARTIAL and quoted deliberately at the word "presumed": this is the hypothesis the study set out to examine by measuring heritability in relatives, not a finding of Mendelian inheritance.
PMID:35031440 SUPPORT Human Clinical
"Mendelian randomization showed significant evidence that negative refractive error (myopia) exerts a direct causal effect over PDS (P = 8.86×10-7)."
The result rather than the method. An earlier revision quoted the methods sentence saying Mendelian randomisation WAS USED to test this, which records that the question was asked and not what the answer was. The answer is what justifies treating myopia as upstream of the disease rather than as a trait that happens to travel with it, and it is why the myopia entry sits where it does in this file.
PMID:35031440 SUPPORT Human Clinical
"Common SNPs relating to the GSAP and GRM5/TYR genes are associated risk factors for the development of PDS and PG."
Names the two loci as risk factors, and note the wording the authors chose: common SNPs relating to genes, associated with risk. That is the register of a susceptibility finding, not of a causal gene, which is why the individual gene entries below are typed SUSCEPTIBILITY.
GSAP
Gene: GSAP hgnc:28042 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GSAP (hgnc:28042). hgnc:28042 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:35031440 SUPPORT Human Clinical
"These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
Gives the lead SNP and the p value, which is the level of detail at which a GWAS locus should be recorded.
TYR
Gene: TYR hgnc:12442 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TYR (hgnc:12442). hgnc:12442 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:35031440 SUPPORT Human Clinical
"These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
PARTIAL because the source reports the locus as GRM5/TYR jointly. The signal cannot be assigned to this gene on this evidence.
GRM5
Gene: GRM5 hgnc:4597 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GRM5 (hgnc:4597). hgnc:4597 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:35031440 SUPPORT Human Clinical
"These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
PARTIAL for the same reason as TYR: the locus is reported jointly and the signal is not resolved to one gene.
💊

Medical Actions

3
Topical Intraocular Pressure Lowering Medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: latanoprost CHEBI:6384 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses latanoprost (CHEBI:6384). CHEBI:6384 is a therapeutic agent from Chemical Entities of Biological Interest. timolol CHEBI:39465 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses timolol (CHEBI:39465). CHEBI:39465 is a therapeutic agent from Chemical Entities of Biological Interest.
The pharmacological arm, and note what it treats: pressure, not pigment. No drug removes deposited pigment or restores trabecular cells, so this is the same topical repertoire used in other open-angle glaucomas, applied once pressure is raised. Prostaglandin analogues increase uveoscleral outflow, beta blockers reduce aqueous production; both act around the obstruction rather than on it. The laser and surgical arms are curated as separate treatments.
Mechanism Target:
INHIBITS Elevated Intraocular Pressure — Lowers pressure by increasing outflow or reducing aqueous production, acting downstream of the trabecular obstruction rather than clearing it.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
Enumerates the management options, all of which act on pressure rather than on the pigment burden.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
The management repertoire as stated in a contemporary review.
Peripheral Laser Iridotomy
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
The one intervention aimed at the mechanism rather than the consequence. By equalising pressure between the posterior and anterior chambers it is intended to flatten the concave iris, break the iridozonular contact, and stop further pigment release. The rationale is coherent and the effect on iris configuration is real; whether it changes clinical outcome is not established, and that gap is curated rather than glossed.
Mechanism Target:
INHIBITS Posterior Iris Concavity and Iridozonular Contact — Aims to abolish the reverse pressure gradient that bows the iris backwards, removing the contact that liberates pigment. This is the only treatment in the entry that addresses the initiating node.
Show evidence (1 reference)
PMID:26871761 SUPPORT Human Clinical
"Topcial medical therapy is usually the first-line treatment; however, peripheral laser iridotomy has been proposed as an alternate treatment."
PARTIAL because the source describes the procedure as proposed rather than established. Quoted verbatim including the source's typographical error in the first word.
Show evidence (1 reference)
PMID:26871761 REFUTE Human Clinical
"However, the effectiveness of peripheral laser iridotomy in reducing the development or progression of pigmentary glaucoma is unknown."
A systematic review concluding that effectiveness is unknown. Recorded as REFUTE of an efficacy claim rather than omitted, because the mechanistic appeal of this procedure is exactly what makes an unevidenced recommendation likely.
Selective Laser Trabeculoplasty
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
Laser applied to the trabecular meshwork, and mechanistically well suited to this disease because it targets pigmented trabecular cells specifically. In a meshwork loaded with melanin there is abundant chromophore, which is both why it works and why it can provoke marked pressure spikes here: treating a heavily pigmented angle delivers more energy than the same settings would elsewhere.
Mechanism Target:
INHIBITS Trabecular Meshwork Pigment Loading and Outflow Dysfunction — Acts on the loaded meshwork itself rather than on pressure downstream. The direction is not in doubt, which is why this is INHIBITS rather than the non-committal MODULATES; what is unsettled is the route, whether it clears pigment, remodels the tissue, or alters trabecular cell behaviour. A caveat specific to this disease: a heavily pigmented angle absorbs more energy at the same settings, so pressure spikes after treatment are more likely here than in other open-angle glaucomas.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
Names selective laser trabeculoplasty among the established management options for this disease.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
Establishes the procedure as part of the management repertoire.
🔬

Diagnosis

1
Gonioscopy
The reference examination, and the one that establishes the diagnosis. It shows an open angle with dense homogeneous pigmentation, which distinguishes this from angle-closure and characterises the pigment distribution. Slit-lamp examination supplies the corneal and iris findings. Diagnosis is clinical throughout; there is no laboratory test.
Show evidence (1 reference)
PMID:29721842 SUPPORT Human Clinical
"CONCLUSIONS: The differential diagnosis of PDS with other disorders can be challenging and awareness of the condition together with meticulous ophthalmologic examination allows early diagnosis followed by appropriate management strategies."
States that the diagnosis rests on careful ophthalmological examination and that distinguishing it from other disorders is genuinely difficult, which is why the examination rather than a test carries the diagnosis.
📊

Prevalence

1
General population
Point Prevalence 1500.0 per 100,000 >1 in 1,000
Roughly 1 to 2 per cent, recorded here at the midpoint. The figure should be read as the prevalence of the dispersion syndrome, not of pigmentary glaucoma, which is substantially rarer. Ascertainment is a real problem: the syndrome is largely asymptomatic and is usually found incidentally at slit lamp examination, so prevalence tracks how carefully people are examined. Prevalence also differs markedly by ancestry, being reported several times higher in people of European than of African or Asian descent.
Show evidence (2 references)
PMID:36518550 SUPPORT Human Clinical
"It is more common in myopic patients with a predominance in young males in the third to fifth decade of life that affects about 1-2% of the population."
Gives the population prevalence range from which the recorded rate is taken.
PMID:36085315 SUPPORT Human Clinical
"Pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) are two stages within the same ophthalmic disease spectrum, which are known to be affected by race."
Supports both the two-stage framing used throughout this entry and the ancestry dependence recorded in the notes.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Pigment Dispersion Syndrome:

Primary open-angle glaucoma
Overlapping Features The main differential once pressure is raised, and distinguished by the anterior segment rather than the disc. Primary open-angle glaucoma lacks the dense homogeneous trabecular pigmentation, the Krukenberg spindle, and the radial iris transillumination defects, and typically presents later than the third to fifth decade.
Pseudoexfoliation syndrome
Overlapping Features The other pigment-associated secondary open-angle glaucoma, and the closest mimic on gonioscopy. Distinguished by the fibrillar white exfoliative material on the lens capsule and pupil margin, by more irregular and often asymmetric angle pigmentation, and by an older population.
Uveitis with pigment release
Overlapping Features Inflammation can liberate pigment and deposit it on the endothelium, producing superficial resemblance. Distinguished by the presence of cells and flare, by inflammatory rather than pigmented keratic precipitates, and by the absence of the iridozonular mechanical geometry.
🐁

Animal Models

1
DBA/2J mouse pigmentary glaucoma
The standard animal model of pigment dispersion progressing to glaucoma. It reproduces the disease sequence faithfully at the level of events, with liberated iris pigment entering the drainage structures, pressure rising and glaucoma following, which is why it has carried most experimental work in this area. Its genetics are the part that does not transfer.
Species
Mouse
Genotype
Gpnmb R150X and Tyrp1 mutations, homozygous
Publication
PMID:11743578
Pathograph links
Trabecular Meshwork Pigment Loading and Outflow Dysfunction partially recapitulates fidelity: moderate Reproduces the pathway from liberated iris pigment through the ocular drainage structures to raised pressure and glaucoma, which is the sequence this entry models downstream of pigment release.
Limitations: The mechanism of pigment liberation differs fundamentally from the human disease. In the mouse it follows from melanosomal protein mutations causing iris pigment dispersion and iris stromal atrophy; in humans it follows from mechanical chafing of a posteriorly bowed iris against the zonules, with no established melanosomal defect. The model therefore informs what happens after pigment reaches the meshwork and not why it is released. Human PMEL, TYRP1 and related melanosomal variants must not be inferred as human disease genes from this model, an error this literature has made before.
Show evidence (1 reference)
PMID:11743578 SUPPORT Model Organism
"Abnormally liberated iris pigment and cell debris enter the ocular drainage structures, leading to increased intraocular pressure (IOP) and glaucoma."
States the sequence the model reproduces, from liberated pigment through the drainage structures to raised pressure and glaucoma.
The genetic findings in this model are curated here as model biology only. The causal alleles are a premature stop in Gpnmb and a Tyrp1 mutation, and their identification in mice has repeatedly been mistaken for evidence implicating the orthologous human genes in pigment dispersion syndrome. This entry deliberately binds no human melanosomal gene for that reason.
Show evidence (1 reference)
PMID:11743578 SUPPORT Model Organism
"DBA/2J (D2) mice develop a form of pigmentary glaucoma involving iris pigment dispersion (IPD) and iris stromal atrophy (ISA)."
Establishes the model and names its two components, one of which, iris stromal atrophy, has no counterpart in the human disease.
{ }

Source YAML

click to show 
name: Pigment Dispersion Syndrome
creation_date: "2026-08-16T00:00:00Z"
description: >-
  Pigment dispersion syndrome is an acquired anterior-segment disorder in which
  pigment is rubbed off the back of the iris and washed forward into the eye's
  drainage system. The mechanism is unusually mechanical for an eye disease: the
  mid-peripheral iris bows backwards into a concave configuration, which brings
  its pigmented posterior surface into contact with the zonular fibres that
  suspend the lens. Every accommodation and every blink chafes iris against
  zonule, liberating granules from the iris pigment epithelium. The released
  pigment circulates in the aqueous humour and settles wherever that fluid goes,
  producing the classical triad: a vertical band of pigment on the corneal
  endothelium, radial spoke-like transillumination defects where the iris has
  been scoured through, and a densely pigmented trabecular meshwork on
  gonioscopy.

  The distinction that organises this entry is that pigment dispersion is a risk
  state, not a glaucoma. Trabecular cells phagocytose small amounts of pigment
  without consequence, and many people carry a heavily pigmented meshwork and
  normal pressure for life. The disease becomes pigmentary glaucoma only when
  sustained pigment loading overwhelms that clearance capacity, outflow
  resistance rises, intraocular pressure climbs, and the optic nerve is damaged.
  The literature is explicit that the same deposited pigment behaves benignly in
  one eye and malignantly in another, and what determines which remains
  unexplained.

  The disease is polygenic rather than Mendelian, with a strong and probably
  causal relationship to myopia, and it presents young, in the third to fifth
  decade, in a population that is disproportionately male when glaucoma
  develops.
category: Complex
disease_term:
  preferred_term: Pigment Dispersion Syndrome
  term:
    id: MONDO:0010896
    label: pigment dispersion syndrome
synonyms:
- PDS
- Pigmentary dispersion syndrome
notes: >-
  Scope. This entry covers the dispersion syndrome and its progression to
  pigmentary glaucoma as one spectrum, because the literature treats them as two
  stages of a single disease and the mechanistic chain is continuous. The
  boundary is nonetheless made explicit at the node level: everything up to and
  including elevated intraocular pressure is dispersion syndrome, and pigmentary
  glaucoma requires glaucomatous optic neuropathy in addition. Curating them as
  separate entries would sever a chain that the pathophysiology does not sever.

  Module conformance. The outflow and optic-neuropathy arm conforms to
  `glaucoma_optic_neuropathy` at three nodes. The disorder-specific substitution
  is the cause of the trabecular dysfunction: here it is progressive loading of
  the meshwork with liberated iris pigment rather than the primary trabecular
  pathology of open-angle glaucoma.

  Genetics deliberately not asserted. This is a polygenic susceptibility, not a
  Mendelian disease. No causal gene is bound, no candidate locus is entered as
  causal, and in particular the melanosomal genes identified in the DBA/2J mouse
  are not curated as human disease genes; that inference is a known error in this
  area and the source deep-research report flags it explicitly.

  Provenance. Built from an Edison Falcon deep-research report. Falcon cites by
  DOI and by internal corpus keys rather than by PMID, and the reference
  validator skips DOI-prefixed snippets, so every DOI in the report was resolved
  to its PubMed record and all evidence here is cited and verified against PMIDs
  instead. The report's own analysis is reflected in the node structure; none of
  its unresolvable corpus-key citations are curated.
pathophysiology:
- name: Posterior Iris Concavity and Iridozonular Contact
  biological_scale: TISSUE
  description: >-
    The initiating mechanical fault. The mid-peripheral iris bows posteriorly
    into a concave configuration, which presses its pigmented back surface
    against the zonular fibres suspending the lens. This is anatomy rather than
    biochemistry: a deep anterior chamber, a wide-open angle, and the axial
    geometry that accompanies myopia all increase the contact, and the movements
    of ordinary life supply the repetition.
  evidence:
  - reference: PMID:10150864
    reference_title: "Pathophysiology of pigment dispersion syndrome and pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The concavity of the midperipheral iris allows iridozonular contact."
    explanation: >-
      States the geometric fault and the contact it permits, which is the whole
      of this node.
  downstream:
  - target: Liberation of Iris Pigment Epithelial Granules
    causal_link_type: DIRECT
    description: >-
      Repeated mechanical contact abrades the pigmented posterior surface.
- name: Liberation of Iris Pigment Epithelial Granules
  biological_scale: CELLULAR
  description: >-
    Pigment granules are released from the iris pigment epithelium, the densely
    pigmented layer on the posterior iris surface. The loss is structural and
    visible: where the epithelium has been scoured away, light passes through the
    iris in radial spoke-like defects, so the damage can be read directly at the
    slit lamp.
  cell_types:
  - preferred_term: iris pigment epithelial cell
    term:
      id: CL:0002565
      label: iris pigment epithelial cell
  evidence:
  - reference: PMID:26871761
    reference_title: "Peripheral iridotomy for pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigment dispersion syndrome is characterized by a structural disturbance in the iris pigment epithelium"
    explanation: >-
      Locates the structural disturbance in the iris pigment epithelium, which is
      the cell layer this node describes.
  downstream:
  - target: Pigment Dispersion Through the Aqueous Humour
    causal_link_type: DIRECT
    description: >-
      Liberated granules enter the aqueous and are carried by its circulation.
  - target: Iris transillumination defect
    causal_link_type: DIRECT
    description: >-
      Loss of the pigmented layer produces the transillumination defects.
- name: Pigment Dispersion Through the Aqueous Humour
  biological_scale: TISSUE
  description: >-
    Released granules circulate in the aqueous humour and deposit wherever that
    fluid carries them: on the corneal endothelium as a vertically oriented
    Krukenberg spindle, on the lens and zonules, and in the trabecular meshwork.
    The distribution is a map of aqueous flow rather than of disease severity,
    which is why the corneal and iris signs are diagnostic without being harmful.
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
    explanation: >-
      Enumerates the three deposition sites that define the clinical
      presentation, which is what this node distributes pigment to.
  downstream:
  - target: Trabecular Meshwork Pigment Loading and Outflow Dysfunction
    causal_link_type: DIRECT
    description: >-
      The consequential destination, because the meshwork is the drain.
  - target: Pigment deposition in the trabecular meshwork
    causal_link_type: DIRECT
    description: >-
      The visible deposit itself, seen on gonioscopy as a dense pigmented band.
      Kept separate from the outflow node because the sign and the functional
      consequence are not the same claim: a heavily pigmented angle can be
      present with normal pressures.
  - target: Corneal pigment deposition (Krukenberg spindle)
    causal_link_type: DIRECT
    description: >-
      Pigment carried by aqueous convection settles on the corneal endothelium
      in a vertical spindle, which is where the flow pattern of the anterior
      chamber writes itself onto the cornea.
- name: Trabecular Meshwork Pigment Loading and Outflow Dysfunction
  biological_scale: TISSUE
  description: >-
    The node where a cosmetic finding becomes a disease, and the point at which
    the two possible courses separate. Trabecular cells phagocytose small amounts
    of pigment and dispose of it without consequence, which is why a densely
    pigmented meshwork is compatible with a lifetime of normal pressure.
    Sustained loading is different: phagocytic and migratory capacity falls,
    trabecular cells are lost, and aqueous outflow resistance rises. The
    literature states the divergence directly, describing the same deposited
    pigment as behaving benignly in some eyes and malignantly in others.
  conforms_to: "glaucoma_optic_neuropathy#Trabecular Meshwork Outflow Dysfunction"
  cell_types:
  - preferred_term: trabecular meshwork cell
    term:
      id: CL:0002367
      label: trabecular meshwork cell
  biological_processes:
  - preferred_term: phagocytosis of pigment granules by trabecular cells
    modifier: DECREASED
    term:
      id: GO:0006909
      label: phagocytosis
  evidence:
  - reference: PMID:10150864
    reference_title: "Pathophysiology of pigment dispersion syndrome and pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Small amounts of pigment are quickly phagocytized."
    explanation: >-
      Establishes the clearance capacity that must be exceeded before pigment
      loading matters, which is why this node is a threshold rather than a step.
  - reference: PMID:10150864
    reference_title: "Pathophysiology of pigment dispersion syndrome and pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Released pigment is carried to the trabecular meshwork where it resides: (1) benignly, not affecting the intraocular pressure, as in pigment dispersion syndrome; or (2) malignantly, elevating the intraocular pressure, as in pigmentary glaucoma."
    explanation: >-
      The decisive sentence of the entry: the same pigment in the same place has
      two possible consequences, and which one occurs is what separates the
      syndrome from the glaucoma.
  downstream:
  - target: Elevated Intraocular Pressure
    causal_link_type: DIRECT
    description: >-
      Rising outflow resistance raises intraocular pressure. This edge fires only
      in the malignant course; in the benign course the node has no downstream
      consequence at all.
- name: Elevated Intraocular Pressure
  biological_scale: TISSUE
  description: >-
    Sustained rise in intraocular pressure as outflow resistance exceeds what
    aqueous production and alternative drainage can compensate for. This node
    exists as a mechanism node rather than only as a clinical sign because it is
    the step that carries the chain forward: pigment in the meshwork does nothing
    to the optic nerve except through pressure, and it is the only point in the
    chain that current treatment can act on.
  conforms_to: "glaucoma_optic_neuropathy#Elevated Intraocular Pressure"
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PDS is a risk factor and can give lead to a rise in intraocular pressure (IOP) and secondary glaucoma."
    explanation: >-
      Establishes the rise in intraocular pressure as the consequence of the
      dispersion and the route to secondary glaucoma. Quoted verbatim including
      the source's grammatical slip.
  - reference: PMID:10150864
    reference_title: "Pathophysiology of pigment dispersion syndrome and pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Released pigment is carried to the trabecular meshwork where it resides: (1) benignly, not affecting the intraocular pressure, as in pigment dispersion syndrome; or (2) malignantly, elevating the intraocular pressure, as in pigmentary glaucoma."
    explanation: >-
      The same sentence that establishes the threshold upstream also names
      pressure elevation as the discriminating consequence, which is why this
      node is the branch point between the two courses.
  downstream:
  - target: Glaucomatous Optic Neuropathy
    causal_link_type: DIRECT
    description: >-
      Sustained pressure elevation damages the optic nerve head, converting the
      dispersion syndrome into pigmentary glaucoma.
  - target: Ocular hypertension
    causal_link_type: DIRECT
    description: >-
      The measurable clinical sign of this node.
- name: Glaucomatous Optic Neuropathy
  biological_scale: TISSUE
  description: >-
    Retinal ganglion cell loss with optic disc and nerve fibre layer damage, and
    the point at which the diagnosis changes name. Pigmentary glaucoma requires
    this node; dispersion syndrome with a heavily pigmented meshwork and a normal
    disc does not qualify, however dramatic the anterior-segment findings.
  conforms_to: "glaucoma_optic_neuropathy#Progressive Glaucomatous Optic Neuropathy"
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmentary glaucoma (PG) can develop from PDS in the presence of elevated IOP coupled with glaucomatous optic neuropathy, retinal nerve fiber thinning, and/or visual field defects."
    explanation: >-
      States the diagnostic requirement precisely: elevated pressure together
      with optic neuropathy, not pigment alone.
  - reference: PMID:26871761
    reference_title: "Peripheral iridotomy for pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmentary glaucoma is a specific form of open-angle glaucoma found in patients with pigment dispersion syndrome."
    explanation: >-
      Places pigmentary glaucoma as a subset arising within the dispersion
      population rather than as a separate disease.
  downstream:
  - target: Glaucoma
    causal_link_type: DIRECT
    description: >-
      Optic neuropathy with characteristic field loss is what converts pigment
      dispersion syndrome into pigmentary glaucoma. This edge is the diagnostic
      threshold rather than a separate biological step.
  - target: Visual field defect
    causal_link_type: DIRECT
    description: >-
      Ganglion cell loss produces the characteristic field defects.
phenotypes:
- name: Iris transillumination defect
  category: Ophthalmic
  description: >-
    Radial, spoke-like mid-peripheral defects where the iris pigment epithelium
    has been abraded away by contact with the zonules, so that light passes
    through the iris. The distribution is a direct map of where the rubbing
    happened, which is why the sign is diagnostic rather than merely associated.
  phenotype_term:
    preferred_term: Iris transillumination defect
    term:
      id: HP:0012805
      label: Iris transillumination defect
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
    explanation: >-
      Names both the corneal deposition and the iris transillumination defects
      that this phenotype covers.
- name: Pigment deposition in the trabecular meshwork
  category: Ophthalmic
  description: >-
    Dense, typically homogeneous pigmentation of the trabecular meshwork on
    gonioscopy, the third leg of the classic triad and the only one of the three
    that sits where the damage happens. Its presence establishes that pigment has
    reached the drain; it does not establish that the drain has failed.
  phenotype_term:
    preferred_term: Pigment deposition in the trabecular meshwork
    term:
      id: HP:0012631
      label: Pigment deposition in the trabecular meshwork
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
    explanation: >-
      Names increased trabecular meshwork pigmentation among the three defining
      clinical findings.
- name: Corneal pigment deposition (Krukenberg spindle)
  category: Ophthalmic
  description: >-
    Vertically oriented pigment on the corneal endothelium, deposited by aqueous
    convection currents, which is why it takes the shape it does. Diagnostic and
    harmless.
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentation of PDS is defined by the presence of pigmented cells on the corneal endothelium, an increase of pigmentation of the trabecular meshwork, and mid-periphery transillumination defects of the iris."
    explanation: >-
      Names pigmented cells on the corneal endothelium as the first of the three
      defining findings. Left unbound because HPO has no Krukenberg spindle or
      corneal endothelial pigment term; the finding is described rather than
      forced onto a poor fit.
- name: Ocular hypertension
  category: Ophthalmic
  description: >-
    Raised intraocular pressure from increased outflow resistance. It may be
    intermittent, and pigment showers after exercise or pharmacological dilation
    can produce transient spikes, so a single normal reading does not exclude the
    problem.
  phenotype_term:
    preferred_term: Ocular hypertension
    term:
      id: HP:0007906
      label: Ocular hypertension
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PDS is a risk factor and can give lead to a rise in intraocular pressure (IOP) and secondary glaucoma."
    explanation: >-
      Establishes raised intraocular pressure as a consequence of the dispersion
      rather than an independent finding. Quoted verbatim including the source's
      grammatical slip.
- name: Glaucoma
  category: Ophthalmic
  description: >-
    Pigmentary glaucoma, the outcome that defines the malignant course. It is an
    open-angle glaucoma occurring specifically within the dispersion population.
  phenotype_term:
    preferred_term: Pigmentary glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:26871761
    reference_title: "Peripheral iridotomy for pigmentary glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmentary glaucoma is a specific form of open-angle glaucoma found in patients with pigment dispersion syndrome."
    explanation: >-
      Defines the phenotype as an open-angle glaucoma arising in this specific
      population.
- name: Myopia
  category: Ophthalmic
  description: >-
    Short-sightedness, present in the great majority of affected people and
    probably causal rather than merely associated. Mendelian randomisation has
    been used specifically to test whether refractive error exerts a causal
    effect on the dispersion syndrome, which is a stronger claim than the usual
    observational association.
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is more common in myopic patients with a predominance in young males in the third to fifth decade of life that affects about 1-2% of the population."
    explanation: >-
      Gives the myopic predominance, the sex skew, and the age of presentation in
      one sentence. No frequency band is assigned: the sentence establishes that
      the disease is more common in myopic patients without quantifying the
      proportion of patients who are myopic, and a band would assert a number the
      source does not report.
- name: Visual field defect
  category: Ophthalmic
  description: >-
    Glaucomatous field loss, typically arcuate or nasal-step, and usually
    asymptomatic until advanced. Its presence marks established optic nerve
    damage rather than dispersion alone.
  phenotype_term:
    preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigmentary glaucoma (PG) can develop from PDS in the presence of elevated IOP coupled with glaucomatous optic neuropathy, retinal nerve fiber thinning, and/or visual field defects."
    explanation: >-
      Names visual field defects among the findings that establish glaucomatous
      damage.
genetic:
- name: Polygenic susceptibility to pigment dispersion
  relationship_type: SUSCEPTIBILITY
  notes: >-
    No causal gene is bound because none is established. Familial clustering has
    sometimes looked autosomal dominant with reduced penetrance, and heritability
    has been measured directly in relatives, but genome-wide association work
    identifies common susceptibility loci rather than a Mendelian gene. The same
    work used Mendelian randomisation to test whether refractive error is
    causally upstream of the disease, which reframes myopia as part of the
    mechanism rather than a co-occurring trait.

    Deliberately not curated: the melanosomal genes identified in the DBA/2J
    mouse model of pigment dispersion. Inferring human causal genes from that
    model is a recognised error in this literature, and the source deep-research
    report flags it explicitly as something not to enter.
  evidence:
  - reference: PMID:30796891
    reference_title: "The Heritability of Pigment Dispersion Syndrome and Pigmentary Glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) are presumed to be inherited in an autosomal dominant manner."
    explanation: >-
      PARTIAL and quoted deliberately at the word "presumed": this is the
      hypothesis the study set out to examine by measuring heritability in
      relatives, not a finding of Mendelian inheritance.
  - reference: PMID:35031440
    reference_title: "Genome-Wide Association Study Identifies Two Common Loci Associated with Pigment Dispersion Syndrome/Pigmentary Glaucoma and Implicates Myopia in its Development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mendelian randomization showed significant evidence that negative refractive error (myopia) exerts a direct causal effect over PDS (P = 8.86×10-7)."
    explanation: >-
      The result rather than the method. An earlier revision quoted the methods
      sentence saying Mendelian randomisation WAS USED to test this, which
      records that the question was asked and not what the answer was. The answer
      is what justifies treating myopia as upstream of the disease rather than as
      a trait that happens to travel with it, and it is why the myopia entry sits
      where it does in this file.
  - reference: PMID:35031440
    reference_title: "Genome-Wide Association Study Identifies Two Common Loci Associated with Pigment Dispersion Syndrome/Pigmentary Glaucoma and Implicates Myopia in its Development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common SNPs relating to the GSAP and GRM5/TYR genes are associated risk factors for the development of PDS and PG."
    explanation: >-
      Names the two loci as risk factors, and note the wording the authors chose:
      common SNPs relating to genes, associated with risk. That is the register
      of a susceptibility finding, not of a causal gene, which is why the
      individual gene entries below are typed SUSCEPTIBILITY.
- name: GSAP
  gene_term:
    preferred_term: GSAP
    term:
      id: hgnc:28042
      label: GSAP
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Gamma secretase activator protein, one of two loci reaching genome-wide
    significance. The gene is better known from amyloid biology, and its route to
    an iris pigment phenotype is not established; it is recorded as a locus, not
    as a mechanism.
  evidence:
  - reference: PMID:35031440
    reference_title: "Genome-Wide Association Study Identifies Two Common Loci Associated with Pigment Dispersion Syndrome/Pigmentary Glaucoma and Implicates Myopia in its Development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
    explanation: >-
      Gives the lead SNP and the p value, which is the level of detail at which a
      GWAS locus should be recorded.
- name: TYR
  gene_term:
    preferred_term: TYR
    term:
      id: hgnc:12442
      label: TYR
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Tyrosinase, the rate-limiting enzyme of melanin synthesis, at the second
    locus. Of the genes implicated this is the one that makes immediate sense in
    a disease about liberated pigment granules, but the association is with a
    lead SNP in a GRM5/TYR interval rather than with TYR specifically, so the
    apparent mechanistic fit is a reason for interest and not a reason to upgrade
    the claim. The neighbouring GRM5 is curated separately for that reason.
  evidence:
  - reference: PMID:35031440
    reference_title: "Genome-Wide Association Study Identifies Two Common Loci Associated with Pigment Dispersion Syndrome/Pigmentary Glaucoma and Implicates Myopia in its Development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
    explanation: >-
      PARTIAL because the source reports the locus as GRM5/TYR jointly. The
      signal cannot be assigned to this gene on this evidence.
- name: GRM5
  gene_term:
    preferred_term: GRM5
    term:
      id: hgnc:4597
      label: GRM5
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Glutamate metabotropic receptor 5, the other half of the second locus. Listed
    alongside TYR rather than instead of it, because the association is with an
    interval containing both and neither can be singled out from this study.
  evidence:
  - reference: PMID:35031440
    reference_title: "Genome-Wide Association Study Identifies Two Common Loci Associated with Pigment Dispersion Syndrome/Pigmentary Glaucoma and Implicates Myopia in its Development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These loci and follow-up analyses implicate the genes gamma secretase activator protein (GSAP) (lead single nucleotide polymorphism [SNP]: rs9641220, P = 6.0×10-10) and glutamate metabotropic receptor 5 (GRM5)/TYR (lead SNP: rs661177, P = 3.9×10-9) as important factors in disease risk."
    explanation: >-
      PARTIAL for the same reason as TYR: the locus is reported jointly and the
      signal is not resolved to one gene.
treatments:
- name: Topical Intraocular Pressure Lowering Medication
  description: >-
    The pharmacological arm, and note what it treats: pressure, not pigment. No
    drug removes deposited pigment or restores trabecular cells, so this is the
    same topical repertoire used in other open-angle glaucomas, applied once
    pressure is raised. Prostaglandin analogues increase uveoscleral outflow,
    beta blockers reduce aqueous production; both act around the obstruction
    rather than on it. The laser and surgical arms are curated as separate
    treatments.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: latanoprost
      term:
        id: CHEBI:6384
        label: latanoprost
    - preferred_term: timolol
      term:
        id: CHEBI:39465
        label: timolol
  target_mechanisms:
  - target: Elevated Intraocular Pressure
    treatment_effect: INHIBITS
    description: >-
      Lowers pressure by increasing outflow or reducing aqueous production,
      acting downstream of the trabecular obstruction rather than clearing it.
    evidence:
    - reference: PMID:29721842
      reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
      explanation: >-
        Enumerates the management options, all of which act on pressure rather
        than on the pigment burden.
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
    explanation: >-
      The management repertoire as stated in a contemporary review.
- name: Peripheral Laser Iridotomy
  description: >-
    The one intervention aimed at the mechanism rather than the consequence. By
    equalising pressure between the posterior and anterior chambers it is
    intended to flatten the concave iris, break the iridozonular contact, and
    stop further pigment release. The rationale is coherent and the effect on
    iris configuration is real; whether it changes clinical outcome is not
    established, and that gap is curated rather than glossed.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Posterior Iris Concavity and Iridozonular Contact
    treatment_effect: INHIBITS
    description: >-
      Aims to abolish the reverse pressure gradient that bows the iris backwards,
      removing the contact that liberates pigment. This is the only treatment in
      the entry that addresses the initiating node.
    evidence:
    - reference: PMID:26871761
      reference_title: "Peripheral iridotomy for pigmentary glaucoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Topcial medical therapy is usually the first-line treatment; however, peripheral laser iridotomy has been proposed as an alternate treatment."
      explanation: >-
        PARTIAL because the source describes the procedure as proposed rather
        than established. Quoted verbatim including the source's typographical
        error in the first word.
  evidence:
  - reference: PMID:26871761
    reference_title: "Peripheral iridotomy for pigmentary glaucoma."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the effectiveness of peripheral laser iridotomy in reducing the development or progression of pigmentary glaucoma is unknown."
    explanation: >-
      A systematic review concluding that effectiveness is unknown. Recorded as
      REFUTE of an efficacy claim rather than omitted, because the mechanistic
      appeal of this procedure is exactly what makes an unevidenced
      recommendation likely.
- name: Selective Laser Trabeculoplasty
  description: >-
    Laser applied to the trabecular meshwork, and mechanistically well suited to
    this disease because it targets pigmented trabecular cells specifically. In a
    meshwork loaded with melanin there is abundant chromophore, which is both why
    it works and why it can provoke marked pressure spikes here: treating a
    heavily pigmented angle delivers more energy than the same settings would
    elsewhere.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Trabecular Meshwork Pigment Loading and Outflow Dysfunction
    treatment_effect: INHIBITS
    description: >-
      Acts on the loaded meshwork itself rather than on pressure downstream. The
      direction is not in doubt, which is why this is INHIBITS rather than the
      non-committal MODULATES; what is unsettled is the route, whether it clears
      pigment, remodels the tissue, or alters trabecular cell behaviour. A
      caveat specific to this disease: a heavily pigmented angle absorbs more
      energy at the same settings, so pressure spikes after treatment are more
      likely here than in other open-angle glaucomas.
    evidence:
    - reference: PMID:29721842
      reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
      explanation: >-
        Names selective laser trabeculoplasty among the established management
        options for this disease.
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management is based on medical therapy, laser iridotomy, selective laser trabeculoplasty, and filtration procedures."
    explanation: >-
      Establishes the procedure as part of the management repertoire.
animal_models:
- name: DBA/2J mouse pigmentary glaucoma
  species: Mouse
  genotype: Gpnmb R150X and Tyrp1 mutations, homozygous
  publication: PMID:11743578
  description: >-
    The standard animal model of pigment dispersion progressing to glaucoma. It
    reproduces the disease sequence faithfully at the level of events, with
    liberated iris pigment entering the drainage structures, pressure rising and
    glaucoma following, which is why it has carried most experimental work in
    this area. Its genetics are the part that does not transfer.
  modeled_mechanisms:
  - target: Trabecular Meshwork Pigment Loading and Outflow Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the pathway from liberated iris pigment through the ocular
      drainage structures to raised pressure and glaucoma, which is the sequence
      this entry models downstream of pigment release.
    limitations: >-
      The mechanism of pigment liberation differs fundamentally from the human
      disease. In the mouse it follows from melanosomal protein mutations causing
      iris pigment dispersion and iris stromal atrophy; in humans it follows from
      mechanical chafing of a posteriorly bowed iris against the zonules, with no
      established melanosomal defect. The model therefore informs what happens
      after pigment reaches the meshwork and not why it is released. Human PMEL,
      TYRP1 and related melanosomal variants must not be inferred as human disease
      genes from this model, an error this literature has made before.
    evidence:
    - reference: PMID:11743578
      reference_title: "Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Abnormally liberated iris pigment and cell debris enter the ocular drainage structures, leading to increased intraocular pressure (IOP) and glaucoma."
      explanation: >-
        States the sequence the model reproduces, from liberated pigment through
        the drainage structures to raised pressure and glaucoma.
  evidence:
  - reference: PMID:11743578
    reference_title: "Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "DBA/2J (D2) mice develop a form of pigmentary glaucoma involving iris pigment dispersion (IPD) and iris stromal atrophy (ISA)."
    explanation: >-
      Establishes the model and names its two components, one of which, iris
      stromal atrophy, has no counterpart in the human disease.
  notes: >-
    The genetic findings in this model are curated here as model biology only.
    The causal alleles are a premature stop in Gpnmb and a Tyrp1 mutation, and
    their identification in mice has repeatedly been mistaken for evidence
    implicating the orthologous human genes in pigment dispersion syndrome. This
    entry deliberately binds no human melanosomal gene for that reason.
diagnosis:
- name: Gonioscopy
  description: >-
    The reference examination, and the one that establishes the diagnosis. It
    shows an open angle with dense homogeneous pigmentation, which distinguishes
    this from angle-closure and characterises the pigment distribution. Slit-lamp
    examination supplies the corneal and iris findings. Diagnosis is clinical
    throughout; there is no laboratory test.
  evidence:
  - reference: PMID:29721842
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: a review and update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONCLUSIONS: The differential diagnosis of PDS with other disorders can be challenging and awareness of the condition together with meticulous ophthalmologic examination allows early diagnosis followed by appropriate management strategies."
    explanation: >-
      States that the diagnosis rests on careful ophthalmological examination and
      that distinguishing it from other disorders is genuinely difficult, which is
      why the examination rather than a test carries the diagnosis.
discussions:
- discussion_id: pds_benign_versus_malignant_course
  prompt: >-
    Why does trabecular pigment loading raise intraocular pressure in some eyes
    and not others, when the deposited pigment looks the same?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Trabecular Meshwork Pigment Loading and Outflow Dysfunction
  rationale: >-
    This is the central unresolved question of the disease and it is unusually
    sharply posed, because the literature states the divergence explicitly: the
    same pigment carried to the same structure behaves benignly in some eyes and
    malignantly in others. A person may carry a densely pigmented meshwork for
    decades with normal pressure while another with comparable gonioscopic
    findings develops glaucoma. Candidate explanations include differences in
    trabecular phagocytic reserve, in the rate rather than the total burden of
    pigment delivery, in baseline outflow facility, and in genetic susceptibility
    at the identified association loci, but none has been shown to determine the
    outcome. Until it is understood, pigment burden on gonioscopy cannot be used
    to predict who needs treatment, which is precisely the clinical question the
    finding appears to answer and does not.
  proposed_experiments:
  - experiment_id: pds_longitudinal_outflow_facility
    name: Longitudinal outflow facility against pigment burden in dispersion syndrome
    description: >-
      Follow a cohort with gonioscopically graded pigment burden using serial
      tonography or equivalent measures of outflow facility, rather than pressure
      alone, and test whether baseline or declining facility separates those who
      convert to ocular hypertension from those who do not at equivalent pigment
      load. Pressure is a late and buffered readout; facility is the quantity the
      mechanism actually predicts.
- discussion_id: pds_iridotomy_mechanism_versus_outcome
  prompt: >-
    Does flattening the iris with peripheral laser iridotomy, which
    demonstrably alters iris configuration, change the clinical course of
    pigment dispersion?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Posterior Iris Concavity and Iridozonular Contact
  - treatments#Peripheral Laser Iridotomy
  rationale: >-
    The procedure targets the initiating mechanism directly and its anatomical
    effect is not in doubt, which makes it unusually persuasive. A systematic
    review nonetheless concludes that its effectiveness in reducing the
    development or progression of pigmentary glaucoma is unknown. The gap matters
    because mechanistic plausibility is doing the work that evidence normally
    would: the intervention is offered on the strength of the mechanism curated
    in this entry, and if pigment liberation is not in fact rate-limiting for
    conversion, flattening the iris could alter the anatomy without altering the
    outcome.
  proposed_experiments:
  - experiment_id: pds_iridotomy_conversion_trial
    name: Randomised trial of iridotomy with conversion to ocular hypertension as endpoint
    description: >-
      Randomise people with dispersion syndrome and normal pressure to iridotomy
      or observation, with conversion to ocular hypertension and to glaucomatous
      optic neuropathy as endpoints rather than iris configuration or pigment
      score. The anatomical effect is already established; what is missing is
      whether it propagates to the outcome.
differential_diagnoses:
- name: Primary open-angle glaucoma
  description: >-
    The main differential once pressure is raised, and distinguished by the
    anterior segment rather than the disc. Primary open-angle glaucoma lacks the
    dense homogeneous trabecular pigmentation, the Krukenberg spindle, and the
    radial iris transillumination defects, and typically presents later than the
    third to fifth decade.
- name: Pseudoexfoliation syndrome
  description: >-
    The other pigment-associated secondary open-angle glaucoma, and the closest
    mimic on gonioscopy. Distinguished by the fibrillar white exfoliative
    material on the lens capsule and pupil margin, by more irregular and often
    asymmetric angle pigmentation, and by an older population.
- name: Uveitis with pigment release
  description: >-
    Inflammation can liberate pigment and deposit it on the endothelium,
    producing superficial resemblance. Distinguished by the presence of cells and
    flare, by inflammatory rather than pigmented keratic precipitates, and by the
    absence of the iridozonular mechanical geometry.
prevalence:
- population: General population
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1500.0
  notes: >-
    Roughly 1 to 2 per cent, recorded here at the midpoint. The figure should be
    read as the prevalence of the dispersion syndrome, not of pigmentary
    glaucoma, which is substantially rarer. Ascertainment is a real problem: the
    syndrome is largely asymptomatic and is usually found incidentally at slit
    lamp examination, so prevalence tracks how carefully people are examined.
    Prevalence also differs markedly by ancestry, being reported several times
    higher in people of European than of African or Asian descent.
  evidence:
  - reference: PMID:36518550
    reference_title: "Pigment dispersion syndrome: A brief overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is more common in myopic patients with a predominance in young males in the third to fifth decade of life that affects about 1-2% of the population."
    explanation: >-
      Gives the population prevalence range from which the recorded rate is
      taken.
  - reference: PMID:36085315
    reference_title: "Pigment dispersion syndrome and pigmentary glaucoma: overview and racial disparities."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) are two stages within the same ophthalmic disease spectrum, which are known to be affected by race."
    explanation: >-
      Supports both the two-stage framing used throughout this entry and the
      ancestry dependence recorded in the notes.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Pigment Dispersion Syndrome: Disease-Characteristics Research Report
Edison Scientific Literature 16 citations 2026-08-16T20:06:12.522122

Pigment Dispersion Syndrome: Disease-Characteristics Research Report

Executive summary

Pigment dispersion syndrome (PDS) is an acquired, usually bilateral anterior-segment disorder in which mechanical contact between the posterior iris pigment epithelium and lens zonules releases pigment into the aqueous humor. Pigment is deposited on the corneal endothelium, lens/zonules, and—most importantly—the trabecular meshwork. Progressive trabecular pigment loading, cellular dysfunction, and cell loss can increase aqueous-outflow resistance and intraocular pressure (IOP). Pigmentary glaucoma (PG) is diagnosed when PDS is accompanied by glaucomatous optic neuropathy and corresponding visual-field loss. PDS alone is therefore a risk state rather than synonymous with glaucoma. The retrieved review estimates that approximately 25–50% of people with PDS develop ocular hypertension, although published progression estimates vary substantially with population, referral setting, and diagnostic definitions. (buffault2020thetrabecularmeshwork pages 13-16)

Domain Established finding Suggested ontology terms Evidence type/strength
Definition Ocular pigment dispersion syndrome (PDS) is an anterior-segment disorder in which pigment granules are released from the posterior iris, disperse through the aqueous humor, and accumulate in structures including the trabecular meshwork; this can raise intraocular pressure (IOP) and progress to pigmentary glaucoma (PG). (buffault2020thetrabecularmeshwork pages 13-16, buffault2020thetrabecularmeshwork pages 19-21) Suggested: MONDO pigment dispersion syndrome; MeSH Pigment Dispersion Syndrome; NCIT pigmentary glaucoma; GO aqueous humor outflow Human clinical + review synthesis; moderate-to-strong
Classic triad The classic ophthalmic signs are typically described as midperipheral iris transillumination defects, a Krukenberg spindle on the corneal endothelium, and dense trabecular meshwork pigmentation on gonioscopy. Pigment deposition in the angle is a key clinical observation. (buffault2020thetrabecularmeshwork pages 19-21) Suggested HPO: iris transillumination defect; corneal pigmentation/Krukenberg spindle; abnormal trabecular meshwork pigmentation Established clinical phenotype; moderate
Mechanism The leading mechanism is mechanical contact between lens zonular fibers and the posterior iris, causing release of iris pigment. Progressive pigment loading of the trabecular meshwork contributes to dysfunction, reduced phagocytosis and migration, increased stress fibers/cell contraction, loss of trabecular cells, and increased outflow resistance, producing ocular hypertension and possibly PG. (buffault2020thetrabecularmeshwork pages 13-16) Suggested GO: phagocytosis; cell migration; actin filament organization; regulation of actomyosin structure organization; aqueous humor outflow; response to mechanical stimulus Human clinicopathologic + experimental support; strong for mechanical/outflow model, moderate for downstream cellular details
Main anatomy/cells Primary affected structures are the posterior iris, lens zonules, aqueous humor pathway, trabecular meshwork, and Schlemm canal. Key cell types include iris pigment epithelial cells/melanocyte-lineage cells and trabecular meshwork cells. The posterior trabecular meshwork is the more pigmented filtering region clinically. (buffault2020thetrabecularmeshwork pages 13-16, buffault2020thetrabecularmeshwork pages 19-21) Suggested UBERON: iris, posterior iris epithelium, lens zonule, anterior chamber, trabecular meshwork, Schlemm canal; Suggested CL: trabecular meshwork cell; iris pigment epithelial cell Anatomy/clinicopathology; strong
Progression to pigmentary glaucoma Not all PDS cases progress, but pigment accumulation can lead to ocular hypertension and PG. One review-level source states that 25-50% of patients with PDS are at risk of developing ocular hypertension. (buffault2020thetrabecularmeshwork pages 13-16) Suggested HPO: ocular hypertension; open-angle glaucoma; elevated intraocular pressure Human observational/review evidence; moderate, quantitative estimate should be treated as literature-derived range
Risk profile PDS is associated clinically with pigment accumulation in the angle and can be exacerbated by factors increasing pigment liberation; literature outside the provided context commonly notes younger myopic males as a classic profile, but that demographic detail is not directly supported in the available context set and should be labeled as external if used in the main report. Within available context, the mechanistic risk is posterior iris-zonule contact leading to continued pigment release. (buffault2020thetrabecularmeshwork pages 13-16) Suggested HPO: myopia; abnormal iris anatomy; pigment dispersion Mixed evidence; strong for mechanistic risk, insufficient in-context support for detailed demographic profile
Diagnosis Diagnosis relies on slit-lamp examination and gonioscopy, which assess angle openness, amount of pigmentation, and angle anatomy. Newer adjunctive imaging discussed for trabecular assessment includes anterior-segment OCT, gonioscopy-coupled OCT, and adaptive-optics scanning laser ophthalmoscopy, but gonioscopy remains the practical core exam. (buffault2020thetrabecularmeshwork pages 19-21) Suggested NCIT: gonioscopy; optical coherence tomography; slit-lamp examination; HPO: abnormal anterior chamber angle pigmentation Standard clinical practice; strong for gonioscopy, emerging for advanced imaging
Management Management is stage-based and centers on lowering IOP when ocular hypertension or PG is present. Options include topical medications, laser trabeculoplasty (especially SLT, targeting pigmented trabecular cells), and surgery for uncontrolled disease. ROCK inhibitors act on trabecular cytoskeleton/ECM pathways; trabeculectomy and nonpenetrating deep sclerectomy lower IOP more substantially than trabecular MIGS but with more risk. (buffault2020thetrabecularmeshwork pages 16-19, buffault2020thetrabecularmeshwork pages 19-21) Suggested NCIT: prostaglandin analog therapy; Rho kinase inhibitor therapy; selective laser trabeculoplasty; trabeculectomy; minimally invasive glaucoma surgery Human therapeutic evidence + review synthesis; moderate-to-strong
Evidence caveat The available context strongly supports trabecular/anterior-segment pathophysiology and management principles, but does not provide definitive in-context support for exact disease identifiers, all phenotype frequencies, or genetic loci; those should be sourced separately in the full report. (buffault2020thetrabecularmeshwork pages 16-19, buffault2020thetrabecularmeshwork pages 13-16, buffault2020thetrabecularmeshwork pages 19-21) Suggested evidence tags: human clinical; review; experimental model High-confidence limitation statement

Table: This table summarizes high-yield, knowledge-base-ready findings for ocular pigment dispersion syndrome, including core definition, mechanisms, anatomy, diagnosis, and management. It also distinguishes supported findings from areas where ontology mappings or evidence remain provisional.

1. Disease information

Definition and terminology

The classic clinical phenotype comprises: (1) radial, mid-peripheral iris transillumination defects; (2) vertically oriented pigment on the corneal endothelium—the Krukenberg spindle; and (3) dense, typically homogeneous trabecular-meshwork pigmentation on gonioscopy. Additional findings include a deep anterior chamber, concave posterior iris configuration, pigment on the anterior lens/zonules (including a Zentmayer/Scheie line), and episodic pigment release. Gonioscopy remains central because it directly establishes an open angle and characterizes pigment distribution. (buffault2020thetrabecularmeshwork pages 13-16, buffault2020thetrabecularmeshwork pages 19-21)

Synonyms: pigmentary dispersion syndrome; pigment dispersion; pigmentary glaucoma syndrome when glaucomatous injury is included. “Pigmentary glaucoma” should not be used for PDS without optic-nerve damage.

Identifiers requiring database verification at ingestion:

  • MeSH: Pigment Dispersion Syndrome.
  • ICD-10-CM: PDS is generally represented under H21.23- (iris transillumination/pigment-dispersion category, laterality-specific); pigmentary glaucoma uses H40.13-, with laterality and stage extensions.
  • ICD-11: classify under secondary open-angle glaucoma/pigment-dispersion entities; the exact current browser code should be validated before production use.
  • OMIM: historical linkage entries exist for pigment-dispersion/pigmentary-glaucoma susceptibility, but PDS is not a validated single-gene Mendelian disorder.
  • Orphanet: no established rare-disease entity was confirmed.
  • MONDO: an exact stable identifier was not confirmed by the retrieved corpus and should not be inferred.

This report describes aggregated disease-level evidence, not individual EHR observations. Patient-level findings should retain laterality, date, IOP, optic-disc/OCT measurements, visual-field indices, and treatment status.

2. Etiology and risk/protective factors

Causal factors

The best-supported proximal cause is anatomical-mechanical: posterior bowing of the mid-peripheral iris permits rubbing against anterior zonular bundles, liberating pigment from iris pigment epithelial cells. Released granules reach the conventional aqueous outflow pathway. Trabecular cells initially phagocytose pigment, but sustained loading reduces phagocytosis and migration, increases actin stress fibers and contraction, and is associated with trabecular-cell loss. Outflow resistance and IOP then rise. (buffault2020thetrabecularmeshwork pages 13-16)

Risk factors

  • Ocular anatomy: posterior iris concavity, deep anterior chamber, wide-open angle, and greater iris–zonule contact.
  • Myopia: the strongest repeatedly observed phenotypic association; recent GWAS work also implicates myopia-related genetic architecture.
  • Age/sex: clinically recognized most often in young-to-middle-aged myopic adults, with men tending to present earlier and to have a higher risk of PG. Women may present later.
  • Family history/genetics: familial clustering and measurable heritability support polygenic susceptibility, but no single gene explains routine human PDS.
  • IOP at presentation: elevated baseline IOP is the most useful clinical predictor of progression.
  • Pigment-liberating events: vigorous exercise, accommodation, pharmacologic dilation, and blinking can produce transient pigment showers in susceptible eyes, but exercise restriction is not routinely justified because evidence of long-term harm is weak.

Protective factors and gene–environment interaction

No reproducible protective allele, diet, supplement, occupational intervention, or medication prevents PDS. Age-related lens enlargement and altered iris configuration may reduce active pigment liberation—the clinical “burn-out” or pigment-reversal phase—but prior trabecular/optic-nerve injury remains. A plausible gene–environment model is that inherited myopia/anterior-segment geometry creates susceptibility while repeated mechanical iris–zonule contact determines pigment exposure; this remains incompletely quantified.

No infectious etiology, toxin, radiation exposure, smoking association, or autoimmune cause is established.

3. Phenotypes

Phenotype Type and course Suggested HPO annotation
Iris transillumination defects Clinical sign; radial mid-peripheral defects; often bilateral but asymmetric Iris transillumination defect
Krukenberg spindle Corneal endothelial pigment; usually vertical; may be incomplete Abnormal corneal pigmentation
Dense angle pigmentation Gonioscopic sign; typically 360° and homogeneous Abnormal pigmentation of trabecular meshwork/anterior chamber angle
Posterior iris concavity Anatomical sign; dynamic and potentially reversible after iridotomy Abnormal iris morphology
Pigment in anterior chamber Episodic clinical sign; may follow dilation or exertion Abnormality of aqueous humor/anterior chamber
Ocular hypertension Laboratory/physiologic abnormality; intermittent or persistent Elevated intraocular pressure (HP:0007906)
Myopia Frequent associated ocular phenotype Myopia (HP:0000545)
Glaucomatous optic neuropathy Progressive complication defining PG Glaucoma (HP:0000501); optic-nerve atrophy
Visual-field loss Usually initially asymptomatic; arcuate/nasal-step defects with PG Visual field defect (HP:0001123)
Halos, blur, ocular discomfort Uncommon episodic symptoms during pigment/IOP spikes Blurred vision; visual halos; ocular pain

PDS commonly begins without symptoms. Quality of life is usually unaffected until recurrent IOP symptoms, treatment burden, or glaucomatous field loss develops. Advanced PG can impair driving, mobility, contrast sensitivity, work, and medication-related ocular comfort. PDS-specific validated quality-of-life statistics are scarce.

4. Genetic and molecular information

Human PDS/PG should presently be annotated as complex, polygenic, incompletely penetrant susceptibility, not a monogenic disease. Familial aggregation has sometimes resembled autosomal-dominant transmission with variable penetrance, but this does not establish a clinically actionable causal gene.

A 2022 GWAS, “Genome-wide association study identifies two common loci associated with pigment dispersion syndrome/pigmentary glaucoma and implicates myopia in its development,” is the most important recent genetics study identified (Ophthalmology, online 2022; DOI: 10.1016/j.ophtha.2022.01.005). Its interpretation is susceptibility rather than Mendelian causality. A 2019 heritability study likewise supports inherited contribution (Tandon et al., American Journal of Ophthalmology, 2019; DOI: 10.1016/j.ajo.2019.02.017).

Knowledge-base cautions:

  • No gene has sufficient evidence for routine PDS single-gene testing.
  • Previously proposed linkage regions/candidate genes should not be entered as definitive causal genes.
  • Human PMEL, TYRP1, or other melanosomal variants must not be inferred from the DBA/2J mouse model.
  • No validated pathogenic/likely pathogenic ClinVar variant, penetrance estimate, carrier frequency, founder mutation, somatic mutation, chromosomal abnormality, anticipation, or germline mosaicism is established for ordinary PDS.
  • No validated epigenetic signature or clinically deployable transcriptomic, proteomic, metabolomic, lipidomic, spatial, or single-cell biomarker was identified.

Accordingly, ACMG variant classification and allele-frequency fields are not applicable unless a patient has a separate syndromic or monogenic glaucoma diagnosis.

5. Environmental and lifestyle information

PDS is not an environmentally acquired pigment disorder. Exercise can transiently increase pigment release in selected individuals, but aerobic activity generally lowers IOP in the broader population; blanket exercise avoidance may therefore cause net harm. A practical approach is to measure IOP and examine the anterior chamber before and after the patient’s triggering activity if reproducible symptoms occur.

Pharmacologic mydriasis can provoke pigment release and an IOP rise; susceptible patients should be monitored after dilation. There is no established role for diet, alcohol restriction, smoking cessation specifically to prevent PDS, although general cardiovascular and ocular-health recommendations remain appropriate. No infectious agent or zoonotic transmission applies.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream anatomy: myopic/deep anterior segment and reverse pupillary-block dynamics promote posterior iris concavity.
  2. Mechanical trigger: posterior iris pigment epithelium contacts zonular fibers.
  3. Pigment release: melanin-containing granules enter the posterior/anterior chambers.
  4. Distribution: aqueous currents deposit pigment on corneal endothelium and concentrate it in the trabecular meshwork.
  5. Trabecular response: phagocytic loading, reduced migration/phagocytosis, actin stress-fiber formation, contraction, and loss of trabecular cells.
  6. Hydrodynamic consequence: conventional outflow resistance increases, producing intermittent or sustained ocular hypertension.
  7. Downstream neural injury: pressure-related retinal ganglion-cell axonal injury causes optic-nerve-head remodeling, retinal nerve-fiber-layer loss, and visual-field defects—PG. (buffault2020thetrabecularmeshwork pages 13-16)

Human tissue evidence indicates more pronounced trabecular-cell loss than in primary open-angle glaucoma, plausibly from pigment-overload toxicity. Experimental pigment exposure reproduces impaired phagocytosis and migration and increased cellular contraction. In a porcine pigmentary-glaucoma model, ROCK inhibition improved phagocytosis and reduced IOP, supporting involvement of Rho/ROCK-regulated cytoskeletal processes. (buffault2020thetrabecularmeshwork pages 13-16)

Suggested GO biological processes: response to mechanical stimulus; phagocytosis; cell migration; actin-filament organization; regulation of cell contraction; aqueous-humor outflow; regulation of intraocular pressure; retinal ganglion-cell axon maintenance; apoptotic process.

Suggested cell types: iris pigment epithelial cell; melanocyte-lineage pigment cell; trabecular meshwork cell; Schlemm-canal endothelial cell; retinal ganglion cell; optic-nerve astrocyte. Exact CL identifiers should be ontology-validated before import.

Inflammation may contribute downstream in experimental glaucoma, but PDS is not primarily an immune-mediated disease. No specific enzyme deficiency, receptor defect, metabolic disease, or protein misfolding mechanism is established.

7. Anatomical structures affected

  • Primary organ/system: eye; anterior segment and aqueous-outflow system.
  • Primary structures: posterior iris pigment epithelium, iris stroma, lens zonules, posterior corneal endothelium, anterior chamber, iridocorneal angle, trabecular meshwork, and Schlemm canal.
  • Secondary structures in PG: optic-nerve head, lamina cribrosa, retinal nerve-fiber layer, retinal ganglion cells, and visual pathway.
  • Localization: characteristically bilateral, frequently asymmetric. Angle pigmentation can be circumferential. The posterior trabecular meshwork is the larger filtering region and accumulates pigment in PDS. (buffault2020thetrabecularmeshwork pages 19-21)
  • Suggested UBERON terms: eye; iris; iris pigment epithelium; zonule of Zinn; anterior chamber of eye; cornea; trabecular meshwork; Schlemm canal; retina; optic nerve.
  • Subcellular structures: melanosome/melanin granule, actin cytoskeleton, phagosome, lysosome, extracellular matrix; suggested GO-CC terms should be attached to the relevant experimental finding rather than asserted as disease-wide abnormalities.

8. Temporal development

PDS usually has insidious onset in early-to-middle adulthood. Active pigment dispersion often precedes ocular hypertension, which may precede PG by years. A useful clinical staging model is:

  1. PDS with normal IOP and normal optic nerve/field.
  2. PDS with ocular hypertension.
  3. Early PG with structural or functional glaucomatous injury.
  4. Moderate/advanced PG.
  5. Late “burn-out” or pigment-reversal phase, in which pigment liberation and IOP may decline while established glaucomatous damage persists.

Natural history is heterogeneous. The frequently cited community cohort by Siddiqui et al. reported conversion to PG of approximately 10% at 5 years and 15% at 15 years, with elevated presenting IOP as the major predictor (published 2003; DOI: 10.1016/S0002-9394(02)02289-4). Referral cohorts have reported higher rates. The broader review literature reports that approximately 25–50% may develop ocular hypertension, which is not equivalent to conversion to glaucoma. (buffault2020thetrabecularmeshwork pages 13-16)

There is no true remission of optic-nerve injury. The critical intervention window is before reproducible retinal nerve-fiber or visual-field loss.

9. Inheritance and population epidemiology

PDS is much more commonly recognized in populations of European ancestry and is less often diagnosed in African and East Asian populations, partly because iris transillumination is harder to detect in heavily pigmented irides and phenotype/distribution may differ. A 2023 review specifically addresses these disparities: Pang et al., Graefe’s Archive for Clinical and Experimental Ophthalmology 261:601–614, published 2023; DOI: 10.1007/s00417-022-05817-0.

Reliable population-wide incidence is unavailable. Commonly cited prevalence estimates are approximately 2–4% in White adults, but estimates depend strongly on ascertainment and should not be treated as globally representative. Men are overrepresented among younger PG cases and generally develop clinically consequential disease earlier; sex differences narrow with age.

Inheritance is multifactorial/polygenic with age-dependent, incomplete penetrance and variable expressivity. There is no established anticipation, founder effect, carrier frequency, consanguinity effect, or clinically relevant germline mosaicism.

10. Diagnostics

Clinical evaluation

Diagnosis is clinical and should include:

  • slit-lamp biomicroscopy before dilation;
  • Goldmann applanation tonometry, preferably on more than one occasion and at different times;
  • gonioscopy documenting angle width and pigment pattern;
  • optic-disc examination/photography;
  • OCT retinal nerve-fiber and ganglion-cell analysis;
  • standard automated perimetry;
  • central corneal thickness for interpreting IOP risk;
  • anterior-segment OCT or ultrasound biomicroscopy when posterior iris concavity/iris–zonule relationships are uncertain.

Gonioscopy remains the practical reference examination. Anterior-segment OCT, gonioscopy-coupled OCT, and adaptive-optics imaging can provide increasingly detailed structural assessment, but do not replace gonioscopy. (buffault2020thetrabecularmeshwork pages 19-21)

There is no diagnostic blood test, urine test, biopsy, circulating biomarker, or validated molecular assay. WES, WGS, glaucoma gene panels, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not routinely indicated for isolated PDS.

Differential diagnosis

  • Pseudoexfoliation syndrome: flaky fibrillar material on lens/pupil margin, patchier angle pigment, older age; systemic extracellular-matrix disorder.
  • Primary open-angle glaucoma: lacks characteristic pigment-dispersion signs.
  • Pigment from uveitis/Fuchs heterochromic iridocyclitis: inflammatory cells, keratic precipitates, heterochromia; pigment distribution differs.
  • Trauma or intraocular surgery: unilateral/asymmetric history and iris injury.
  • Uveitis–glaucoma–hyphema syndrome: malpositioned intraocular lens with inflammation/hyphema.
  • Bilateral acute iris transillumination: acute painful red eye, diffuse rather than radial transillumination, often marked sphincter paralysis.
  • Iris melanoma/pigment epithelial cyst: focal lesion or unilateral pigment release.
  • Angle recession, steroid-induced glaucoma, and melanomalytic glaucoma.

11. Outcome and prognosis

PDS does not shorten life expectancy and has no disease-specific mortality. The relevant outcome is preventable visual disability from PG. Most people with PDS never become blind, especially with surveillance and timely IOP control. Prognosis worsens with higher or fluctuating IOP, younger age at pressure elevation, established optic-nerve/field damage, thin cornea, myopia, family history, and poor treatment adherence.

Structural or functional glaucomatous loss is irreversible, but lowering IOP slows progression. There is no validated molecular prognostic biomarker. Quality-of-life burden is driven by field loss, treatment complexity, cost, ocular-surface toxicity, and surgery rather than pigment dispersion itself.

12. Treatment and current implementation

Stage-based strategy

PDS, normal IOP, no damage: observation with periodic IOP, gonioscopy, optic-disc/OCT, and visual-field assessment. No therapy has proven benefit solely to remove visible pigment.

Ocular hypertension or PG: establish an individualized target IOP. Standard open-angle glaucoma drugs are used:

  • prostaglandin analogues such as latanoprost;
  • topical beta-blockers;
  • alpha-2 agonists;
  • topical carbonic-anhydrase inhibitors;
  • ROCK inhibitors where available;
  • oral carbonic-anhydrase inhibition for urgent short-term control.

Prostaglandin analogues primarily increase uveoscleral outflow and may also remodel trabecular extracellular matrix. ROCK inhibitors directly reduce trabecular cytoskeletal/contractile resistance. Preservative exposure, especially benzalkonium chloride, can promote ocular-surface and trabecular oxidative/inflammatory toxicity; preservative-free formulations are reasonable when treatment burden is high. (buffault2020thetrabecularmeshwork pages 16-19)

Laser trabeculoplasty: SLT targets pigmented trabecular cells and can lower IOP through predominantly cellular and biochemical remodeling. PDS/PG eyes may respond strongly but are also susceptible to post-laser IOP spikes; lower energy, limited initial treatment, and post-procedure IOP monitoring are prudent. Histology suggests minimal mechanical damage from SLT. (buffault2020thetrabecularmeshwork pages 16-19)

Laser peripheral iridotomy (LPI): can flatten posterior iris concavity and reduce iris–zonule contact, but evidence that routine prophylactic LPI prevents glaucoma is insufficient. A 10-year randomized trial found benefit concentrated in eyes selected as high risk by a provocative test rather than supporting universal treatment (Gandolfi et al., JAMA Ophthalmology, 2014; DOI: 10.1001/jamaophthalmol.2014.3291). LPI does not reverse established trabecular or optic-nerve damage.

Surgery: uncontrolled PG is treated using conventional glaucoma pathways—trabeculectomy, glaucoma drainage devices, deep sclerectomy where practiced, or selected angle-based/MIGS procedures. In general glaucoma evidence, trabeculectomy lowers IOP by about 46–51% at two years; MIGS usually offers more modest pressure reduction with faster recovery and fewer serious complications. These figures are not PDS-specific. (buffault2020thetrabecularmeshwork pages 19-21)

Suggested NCIT intervention annotations: intraocular-pressure-lowering therapy; prostaglandin analogue therapy; beta-adrenergic antagonist therapy; carbonic-anhydrase inhibitor therapy; Rho-kinase inhibitor therapy; selective laser trabeculoplasty; laser peripheral iridotomy; trabeculectomy; glaucoma drainage implant; minimally invasive glaucoma surgery.

No approved gene, cell, RNA, immune, or genotype-guided therapy exists. No PDS-specific pharmacogenomic recommendation was identified. A clinical-trial registry query was attempted but rate-limited; the mature interventional literature is dominated by LPI and standard glaucoma treatments rather than disease-modifying molecular therapy.

13. Prevention

  • Primary prevention: unavailable because the predisposing anatomy/genetic architecture cannot currently be modified. Vaccination and antimicrobial prophylaxis are not applicable.
  • Secondary prevention: identify PDS by slit lamp/gonioscopy; document baseline IOP, OCT, and field; follow higher-risk patients more closely; recheck IOP after dilation when appropriate.
  • Tertiary prevention: promptly treat ocular hypertension/PG to prevent irreversible field loss; support adherence; minimize ocular-surface toxicity; escalate to laser or surgery when target IOP is not achieved.
  • Behavior: do not impose general exercise prohibition. Investigate reproducible exercise-associated symptoms individually.
  • Genetic screening/counseling: no carrier, prenatal, preimplantation, or cascade molecular test is indicated. First-degree relatives may reasonably receive routine comprehensive eye examinations because familial aggregation exists.

Population screening specifically for PDS has not demonstrated cost-effectiveness; targeted case finding during comprehensive eye examinations is the practical real-world approach.

14. Other species and natural disease

No infectious transmission or zoonotic potential exists. Naturally occurring pigmentary glaucoma is described in animals, but its anatomy and genetic causes need not match human PDS.

The DBA/2J mouse (Mus musculus, NCBI Taxon 10090) develops age-related iris disease, pigment dispersion, IOP elevation, and retinal ganglion-cell/optic-nerve degeneration. Its phenotype is driven principally by mutations in melanosomal genes Gpnmb and Tyrp1 (Anderson et al., Nature Genetics, 2002; DOI: 10.1038/ng794). This is a powerful inherited pigmentary-glaucoma model but not proof that orthologous genes cause common human PDS.

Dogs and cats can develop pigmentary or secondary glaucomas, sometimes with breed predisposition, but these should not be entered as direct orthologues of human PDS without phenotype- and breed-specific veterinary evidence. No VBO breed annotation is sufficiently supported here.

15. Model organisms and advanced research

DBA/2J mouse

Recapitulates: spontaneous iris pigment disease, angle pigment/debris, age-dependent IOP elevation, retinal ganglion-cell loss, optic-nerve degeneration, neuroinflammation, and variable disease penetrance.

Limitations: iris disease includes stromal atrophy and mechanisms different from simple human posterior iris–zonule rubbing; IOP onset and severity vary by colony/environment; Gpnmb/Tyrp1 biology is not established as the common human cause. The model is best for studying pressure-induced neurodegeneration, immune responses, and modifiers—not as a literal genetic model of human PDS.

Porcine pigmentary-glaucoma models

Pigment is introduced into ex vivo or in vivo porcine anterior segments to model trabecular loading. These models reproduce reduced outflow, IOP elevation, impaired trabecular-cell phagocytosis, and Rho/ROCK-dependent cytoskeletal changes. ROCK inhibition reduced IOP and improved phagocytosis, supporting target validation. (buffault2020thetrabecularmeshwork pages 13-16)

Limitations: acute/artificial pigment exposure does not reproduce lifelong human anatomy, polygenic susceptibility, or optic-neuropathy natural history.

Cell and organ-culture systems

Cultured human trabecular cells and perfused anterior segments permit study of pigment uptake, phagocytosis, cytoskeletal contraction, oxidative stress, extracellular-matrix remodeling, and drug response. Single-cell, spatial-transcriptomic, organoid, CRISPR-screen, and integrated multi-omics findings specifically validated for human PDS remain major research gaps.

Recent developments and expert interpretation

The most consequential recent work is not a new therapy but refinement of disease architecture: the 2022 GWAS supports common-variant susceptibility and a causal/mediating role for myopia; the 2023 disparities review emphasizes that the traditional “young White myopic male” description is incomplete and may reflect ascertainment; and contemporary trabecular research increasingly treats pigmentary glaucoma as a disorder of active cell biology—phagocytic failure, cytoskeletal contraction, and cell loss—rather than simple passive clogging. The therapeutic implication is that trabecular-targeted treatments such as SLT and ROCK inhibition have a mechanistic rationale, although neither removes the upstream anatomical predisposition. (buffault2020thetrabecularmeshwork pages 16-19, buffault2020thetrabecularmeshwork pages 13-16)

Evidence limitations

The retrieval system obtained full-text evidence for trabecular pathophysiology, imaging, and glaucoma treatment but could not retrieve full text for several landmark PDS cohorts, the 2022 GWAS, the 2023 disparities review, or the 2014 LPI trial. Therefore, exact abstract quotations are not reproduced: presenting unverified wording as a direct quote would be inappropriate. URLs and publication dates are supplied for traceability, and quantitative claims are explicitly distinguished as PDS-specific, ocular-hypertension outcomes, or general-glaucoma evidence. Exact MONDO/ICD-11 identifiers, ontology accessions, and all proposed HPO/GO/CL/UBERON mappings should be validated against the current ontology releases before automated knowledge-base ingestion.

References

  1. (buffault2020thetrabecularmeshwork pages 13-16): J. Buffault, A. Labbé, P. Hamard, F. Brignole-Baudouin, and C. Baudouin. The trabecular meshwork: structure, function and clinical implications. a review of the literature. Sep 2020. URL: https://doi.org/10.1016/j.jfo.2020.05.002, doi:10.1016/j.jfo.2020.05.002. This article has 200 citations.

  2. (buffault2020thetrabecularmeshwork pages 19-21): J. Buffault, A. Labbé, P. Hamard, F. Brignole-Baudouin, and C. Baudouin. The trabecular meshwork: structure, function and clinical implications. a review of the literature. Sep 2020. URL: https://doi.org/10.1016/j.jfo.2020.05.002, doi:10.1016/j.jfo.2020.05.002. This article has 200 citations.

  3. (buffault2020thetrabecularmeshwork pages 16-19): J. Buffault, A. Labbé, P. Hamard, F. Brignole-Baudouin, and C. Baudouin. The trabecular meshwork: structure, function and clinical implications. a review of the literature. Sep 2020. URL: https://doi.org/10.1016/j.jfo.2020.05.002, doi:10.1016/j.jfo.2020.05.002. This article has 200 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 8
Resolved 7
Unresolved (possible confabulation) 0
Unverifiable 1

7 of 8 references resolved; the rest could not be looked up either way.